PhRMA’s Revamped Research Awards Aim To Encourage Alzheimer’s “Ecosystem”
Shifting the program from the Discoverers Award, which focused solely on industry achievements, to broader honors acknowledges that “finding the Alzheimer's treatment that works is a tremendous task” which requires “collaboration with our partners” in the scientific and patient advocacy communities, PhRMA President Castellani says.
You may also be interested in...
At the organization’s Research and Hope Awards, the academics won for products that are already on the market, and the pharmaceutical company won for the vaccine that’s still in development.
With the failure of the second of four Janssen-led Phase III trials testing bapineuzumab, partners Janssen and Pfizer have elected to discontinue the bapineuzumab I.V. clinical development program. Nonetheless, the anti-amyloid-beta approach is still alive, as the field turns to early, pre-symptomatic intervention.
Stephen Hahn will go before the Senate health committee less than three weeks after being nominated. Pink Sheet's historical charts illustrate how a long wait and a quick hearing could mean a rapid confirmation.